HLA-C and neoplasm: The first one is tumor-infiltrating lymphocytes (TILs)-based ACT, in which endogenous TILs are expanded ex vivo from a patient’s tumor before being infused back into the patient [50, 51].The second one is engineered T-cell receptor (TCR)-based ACT to recognize specific tumor antigens while it’s limited to major histocompatibility complex (MHC) expressing Ags [51].